P
Phil
End-to-end prescription management and delivery service connecting patients with local pharmacies
About Phil
Phil.us is a healthcare technology startup that aims to revolutionize the way patients access their medications. The company operates in the healthcare and pharmaceutical markets, serving both healthcare providers (HCPs) and patients. Its primary offering is the PhilRx platform, a digital tool designed to streamline the process of obtaining prescribed medications.
The platform's main features include a national dispense network, real-time HIPAA compliant data, and actionable insights. It simplifies the prior authorization process, ensuring that patients can start their therapy without delay. By negotiating formulary access, Phil.us guarantees that prescriptions are covered by insurance, reducing the financial burden on patients.
The company's business model is centered around improving patient adherence to medication regimens and increasing the number of prescriptions covered by insurance. This is achieved by removing barriers to medication access and providing a seamless experience for both patients and healthcare providers.
Phil.us also offers consulting services to help healthcare providers optimize their channel strategies and build effective telemedicine programs. These services aim to improve patient access and drive transformative brand outcomes.
In terms of revenue generation, Phil.us likely makes money through a combination of platform subscription fees from healthcare providers, consultation fees, and possibly a percentage from each prescription filled through their platform.
In conclusion, Phil.us is a promising startup that leverages technology to simplify medication access and improve patient outcomes in the healthcare sector.
Source: Dealroom company dataAt a glance
- Status
- Operational
- Founded
- 2015
- Headquarters
- Scottsdale, United States
- Employees
- 284
- Open positions
- 15
- Dealroom signal
- 83.7/100
- Industry
- Health
- Sub-industry
- Pharmaceutical, Health Platform
- Sector
- Biotech & Life Sciences, Pharmacy, Biotechnology, Patient Care, Biotech and Pharma, Hard Tech, DT and LS, science-based
- Client focus
- b2c
Knowledge graph
More headlines
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| DEBTDebt | Jul 2025 | $60M | — | K2 HealthVentures | ↗ |
| SERIES DOther financing | Jun 2021 | $56M | $224M | Warburg Pincus | — |
Growth signals
Latest recorded traffic for Phil is 330K monthly website visits, up 3.1% over the last three months. Phil's team declined 1.4% over the past year.
Open positions
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Seed9 investors entered at this stage
Eniac Ventures
Jose Marin
Forerunner Ventures
Tom Williams
Fabrice Grinda
SV Angel
Uncork Capital
David Rusenko
FJ Labs
Series A5 investors entered at this stage
Crosslink Capital
Silicon Valley Bank- TCTransmedia Capital
GreatPoint Ventures
Tarsadia Investments
Series B and later2 investors entered at this stage
Warburg Pincus
K2 HealthVentures
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Phil on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Phil’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.







